Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: a Phase I/IB Study
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Lenalidomide (Primary) ; Cetuximab
- Indications Carcinoma; Colorectal cancer; Head and neck cancer; Salivary gland cancer; Squamous cell cancer; Tongue cancer
- Focus Adverse reactions
- 23 Oct 2013 Status changed from recruiting to completed.
- 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
- 28 May 2013 Planned end date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.